Luminoah Raises $25M Series B for Tube Feeding Pump
TL;DR: Luminoah announced a $25 million Series B financing led by Sandbox Clinical Ventures, according to its GlobeNewswire release dated November 10, 2026. citybiz reported the same round. Not all o…

How much of the $25 million is new money?
Only $20 million is new equity. The company's release says the Series B "includes $20 million in new equity capital and $5 million in previously issued convertible notes that converted as part of the financing."
The converted notes were earlier financing that turned into Series B shares. They count toward the headline. They don't add to the company's bank balance today.
| Component | Amount | What it is |
|---|---|---|
| New equity | $20 million | Cash raised in this round |
| Converted notes | $5 million | Earlier convertible notes that became Series B shares |
| Headline total | $25 million | The figure in the announcement |
When you compare rounds across companies, compare the new-money line. Headlines rarely do.
Who invested in Luminoah's Series B?
Sandbox Clinical Ventures led. The release names the Blue Venture Fund, GV (Google Ventures) and Sands Capital as participants. citybiz adds the Texas Medical Center Venture Fund, the CU Healthcare Innovation Fund and the American Gastroenterological Association GI Opportunity Fund to the list.
None of the sources say how large each investor's check was, and neither describes what Sandbox or Sands Capital typically back.
What does Luminoah make, and what will the money do?
Luminoah Flow is an enteral feeding system, meaning a device that delivers nutrition through a tube. citybiz describes it as combining "a pocket-sized, rechargeable feeding pump, nutrition pouches, and a connected mobile app into one system." Traditional pumps often put patients on a pole, and the release says that limits "mobility and independence."
The release says the capital will support three things: expanded distribution of Luminoah Flow, increased manufacturing capacity, and continued development of Luminoah Intelligence, a clinician-facing data platform. That last item addresses a gap the company names itself. Caregivers manage much of the therapy with handwritten logs, and clinicians have limited visibility into how much nutrition patients actually receive.
Neal Piper, a former Pfizer executive, founded the company in 2020, according to citybiz. The name partly honors his son Noah, who used an older tube feeding system during treatment for a rare brain tumor.
What does FDA clearance mean for this round?
It means the device is cleared to be sold, and that changes what the money is for. The company says it received FDA clearance in April 2026 and then "completed an early access program with patients served by leading healthcare institutions in the Pacific Northwest and Southeast."
A company at this stage is no longer funding a regulatory question. It's funding a commercial one. Can it build enough devices, and can it persuade hospitals and caregivers who have used the same kind of pump for years to switch? The sources report no sales, unit volumes or revenue, so you can't tell from this announcement how far along that second question is.
What the announcement doesn't tell you
There is no valuation. The sources also give no ownership stake for the new investors, no terms for the converted notes and no revenue. Reimbursement details are missing too, and they matter a great deal for a device that depends on how insurers and providers pay.
Downside first: a cleared device with a good story can still stall if hospitals are slow to change purchasing, or if manufacturing scale-up costs more than planned. Neither risk shows up in a press release, and none of the sources address them. This is a read on the company's own account, not a verdict.
Common mistakes when reading a medtech Series B
Take the headline as new cash and you'll overstate the company's runway, because a fifth of this round is notes that converted.
A famous name on the investor list is easy to mistake for a due diligence result. GV's participation tells you GV invested. It doesn't tell you what GV learned or at what price.
And if you copy a figure from whichever outlet ranks first, you inherit its errors. Verify before you trust it, and go to the company release or the original report.
FAQ
Who led Luminoah's Series B? Sandbox Clinical Ventures led the round, according to the company's release. Participants include the Blue Venture Fund, GV (Google Ventures) and Sands Capital. citybiz also lists three healthcare-focused funds.
Is Luminoah's feeding system FDA-cleared? The company says Luminoah Flow received FDA clearance in April 2026. After that it ran an early access program with patients at healthcare institutions in the Pacific Northwest and Southeast.
What will Luminoah do with the money? The company says it will expand distribution of Luminoah Flow, increase manufacturing capacity and keep developing Luminoah Intelligence, a data platform for clinicians.
What valuation did the round carry? The sources don't say. Neither the company release nor citybiz states a valuation, so any figure you see elsewhere is unconfirmed.
What to do next
You can't invest in this round, but the same reading applies when an SPV, syndicate or secondary platform pitches you a medtech allocation. Find the line that separates new equity from converted notes, then look for a stated valuation. If the pitch doesn't give one, treat the round as informative about who backs the company and not about price.
For other recent rounds worth reading this way, see Outmarket AI's Series B, Miter's Series B led by Battery Ventures, Tractian's Series D and what a Series B raise timeline looks like.
If you want this kind of downside-first read on private-market deals in your inbox, subscribe to the free AIN briefing.
Educational content only. Not investment, tax, or legal advice. Not an offer or solicitation to buy or sell securities. Past performance does not guarantee future results. Private-market investments are illiquid and involve risk of loss, including total loss of capital. Consult qualified advisers. Angel Investors Network is not a broker-dealer or investment adviser.
Looking for investors?
Browse our directory of 750+ angel investor groups, VCs, and accelerators across the United States.
About the Author
Jeff Barnes, MBAContinue Reading

Charta Health Raises $55M Series B for AI Chart Review

American AI Logistics Closes Series B Led by GOVO

Venture Capital Investors: Who They Are, Who They Fund

SC Ventures and SBI Join Soter Insure's Series B

Team USA Seeks Private Investment in New Venture
